CARR & WADDOUPS

TRENT J. WADDOUPS
TAYLOR D. CARR (1944 – 2001)

ATTORNEYS AT LAW, L.L.C. 609 JUDGE BUILDING 8 EAST BROADWAY SALT LAKE CITY, UTAH 84111

TELEPHONE (801) 363-0888 FACSIMILE (801) 363-8512

May 31, 2017

email: trent@cw-law.net

OTC Markets Group 304 Hudson Street 2nd Floor New York, NY 10013

RE: Unisource Corporate Corporation

Opinion re: Current Information

Ladies and Gentlemen:

This letter is in response to the request that I express my opinion as to whether adequate current public information is available concerning Unisource Corporate Corporation (the "Company" or the "Issuer") and its securities (the "Information"), within the meaning of Rule 144(c)(2) under the Securities Act of 1933. OTC Markets Group is entitled to rely on this letter in determining whether the Issuer has made adequate current Information publicly available within the meaning of Rule 144(c)(2), and may publish this letter on the OTC Markets News Service. I am a U.S. resident, and the law firm of Carr & Waddoups Attorneys at Law, L.L.C. has been retained by the Issuer for the sole purpose of reviewing the current information supplied by the Issuer and rendering this letter and related matters.

Facts and Assumptions

In connection with rendering this opinion, I have investigated such matters and examined such documents as I have deemed necessary. In examining the documents, I have assumed the genuineness of signatures (both manual and conformed), the authenticity of documents submitted as originals, the conformity with originals of all documents furnished as copies, and the correctness of the facts set forth in such documents.

Nothing came to my attention during the course of my investigation that led me to conclude that any such documents were not genuine or authentic or that the facts set forth therein were not true. Any opinion expressed herein relates only to the Company and Information. It should not be relied on by any other person or in connection with any other transaction.

I am authorized to practice law in the State of Utah, and within the United States. This opinion covers, and is rendered under, the laws of the United States. Further, I am permitted to practice before the Securities and Exchange Commission (the "SEC") and have not been prohibited from practice thereunder.

Inquiry and Investigation

As to matters of fact upon which counsel has relied and obtained, directly or indirectly from public officials, including officials of OTC Markets Group, and from officers of the Company and other sources, I have believed such sources to be reliable. I have examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering the letter. Based upon my inquiry of management and the directors of the Company, to the best of my knowledge, neither the Company, its officers or directors, any holder of 5% or more of the securities of the Company, nor is counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

In addition, I have viewed a portion of the information filed by the Company on otemarkets.com, including 15c2-11 information contained in the Company's Annual Report for the period ending December 31, 2016, posted on May 16, 2017, and the quarterly report for March 31, 2017, also posted on May 16, 2017, collectively referred to herein also as the "Information". I also confirmed with OTC Markets that the filings referenced as the Information are the only filings that are necessary in order for the Company to be current with its reporting to OTC Markets, once this letter is filed with OTC Markets.

I have spoken with Daisy Aronce, C.P.A., who is responsible for the preparation of the financial statements and notes thereto contained in the Company's annual and quarterly filings with OTC Markets. Ms. Aronce confirmed that the financial statements are not audited, that she believes these financial statements are materially accurate, and that these financial statements are prepared according to Generally Accepted Accounting Principles.

I have also met and spoken with Nicholas S. Ferber, the sole Officer and Director of the Company. Mr. Ferber and I reviewed and discussed the Information contained in the Company's periodic reports. After inquiry, and to the best of my knowledge and information, neither the Company, any 5%+ shareholder, nor counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

Nicholas S. Ferber and Clifford Grossman both assisted and provided information with regard to the present letter and the Company's Information. I have also inquired and confirmed that no person, firm or entity (including Mr. Ferber and Mr. Grossman and/or any entity in which either has an interest) has received, or will receive, stock or securities as consideration for services rendered to the Company with respect to this letter and/or the Information. I have made specific inquiry of both Mr. Ferber and Mr. Grossman, and based upon these inquiries and other information available to me, I am of the opinion that no sales of securities issued by the Company have been made by any insiders, affiliates, or other restricted individuals or entities in compliance with Rule 144. Moreover, nothing has come to my attention during my investigation and review of the Company and its Information indicating that any of the insiders is in possession of any material non-public information regarding the Company or its securities that would prohibit any of them from buying or selling the Securities under Rules 10b(5) or 10b(5)(1)

of the Securities Exchange Act.

I have spoken with Joslyn Claiborne at Pacific Stock Transfer Company, the Issuer's transfer agent, and have confirmed that Pacific is registered with the SEC. As of March 31, 2017, Pacific Stock Transfer lists the number of issued and outstanding shares of common stock at 78,691,983. However, the Company lists the number of issued and outstanding shares of common stock as of the same date at 75,691,983. Regarding this discrepancy, I have reviewed a Representation Letter from one of the Company's directors, Nicholas Ferber, as well as a Supplemental Information disclosure, filed by the Company with OTC Markets on May 31, 2017. I have also reviewed a legal opinion letter from the company's legal counsel, Michael Labertew, which opines that the 3,000,000 shares in question are void *ab initio*, and I have spoken with Michael Labertew and Ms. Claiborne.

The basis for the discrepancy is that in March 2015, there were two directors: Nicholas Ferber and Jordan Serlin. At that time, and without Mr. Ferber's knowledge, permission, vote or authorization, Mr. Serlin directed the Company's transfer agent to issue 3,000,000 shares for him in March 2015. These shares eventually put in the name of his wife, Melissa Serlin. Mr. Ferber did not become aware of this stock issuance until sometime later, after which Mr. Serlin was no longer an officer or director of the Company. The Company and Mr. Serlin made demands upon Ms. Serlin to return the shares, but she has refused to comply.

The Company's bylaws and articles of incorporation do not allow for the issuance of shares by the Company unless a majority of the board approves the issuance at a meeting or all board members sign a unanimous consent for such issuance. Further, state law requires such board approval before stock can be issued. Mr. Ferber states there was never a meeting related to the 3,000,000 shares referenced above, nor was there ever a unanimous or majority board resolution approving such shares, nor was any consideration ever provided for these shares.

Because the transfer agent was not aware of these issues behind the issuance of the shares, the share certificate for 3,000,000 shares was issued by the Company's transfer agent upon request of Mr. Serlin in March 2015. Regardless of the issuance by the Company's transfer agent, the Company's position, as well as the legal opinion of counsel, is that the 3,000,000 shares in question were never legally authorized for issuance, no consideration was provided for these shares, they are void *ab initio* (from the beginning), and therefore the Company does not acknowledge these shares as being validly authorized and issued, nor does it reflect these shares in its financial statements. The Company has placed a stop transfer on such shares with its transfer agent in case they are ever submitted to them for further transfer. In addition, the Company states that it does not and will not acknowledge such shares in any vote of or distribution to shareholders.

Conclusions

Based on the examination and inquiry as set forth above, I am of the opinion that the Information for and through March 31, 2017 (i) constitutes "adequate current public

information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcmarkets.com, and (iv) has been posted in the OTC Markets News Service.

This opinion may be relied upon by OTC Markets Group in determining whether to permit quotations in the Issuer's securities in the OTC Markets quotation venue. No other persons may rely on such opinion and no other use of this opinion is authorized without the written consent of the undersigned.

Very truly yours,

CARR & WADDOUPS

Trent J. Waddoups